Shenzhen Neptunus Bioengineering Co Ltd (000078) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Shenzhen Neptunus Bioengineering Co Ltd ¥2.76, price ¥1.53, upside +80.4%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shenzhen Neptunus Bioengineering Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥1.29 – ¥5.29 · fair‑value band ¥2.54 – ¥2.95 · the ¥1.53 price screens below the ¥2.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Shenzhen Neptunus Bioengineering Co in your weekly email
Every Wednesday you see whether Shenzhen Neptunus Bioengineering Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China.
Show more
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and offers value-added services for hospitals, medical institutions, and drug retail institutions and distributors. In addition, the company provides drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. It develops HW130 injection that completed the Phase I clinical trial for anti-tumor; and NEP018 for anti-tumor. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
Stock analysis
Shenzhen Neptunus Bioengineering Co Ltd (000078) currently trades at ¥1.53, while our model-based Fair Value estimate is ¥2.76, implying the stock looks roughly 44.6% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥4.67 per share, and 5 of the 6 models we run sit above the ¥1.53 price.
Bear case: the Asset-Based group reads lowest at ¥0.3100, and 1 of the 6 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥2.54 (bear) to ¥2.95 (bull), the price of ¥1.53 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Shenzhen Neptunus Bioengineering Co Ltd reported revenue of 26.7B CNY in FY2025 versus 41.1B CNY in FY2021, a compound −10.2%/yr. Reported net income was −563M CNY in FY2025.
Key figures
Market cap 4.7B CNY (≈ $695M) · P/S ratio 0.18 · EPS (TTM) ¥−0.2200 · Dividend yield 11.0% · Net margin −2.1% · Return on equity −22.8% · Return on assets (EBIT) −1.4% · Operating margin 3.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 71% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 80%, 000078 screens cheaper than that median.
Fair Value models
Bear ¥2.54Fair Value ¥2.76Bull ¥2.95
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−12.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.8%
Start year 2020 (pandemic). Over 10 years: +9.1% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.8% (2020) → 2.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Shenzhen Neptunus Bioengineering Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside+80% · Top 25%
Profitability
Return on assets1% · Below median
Net margin (TTM)−2% · Below median
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth−19% · Bottom 25%
Dividend yield (TTM)11.0% · Top 25%
Balance sheet
Debt / equity0.30× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shenzhen Neptunus Bioengineering Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/000078
Frequently asked questions
Is Shenzhen Neptunus Bioengineering Co Ltd (000078) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥2.76 versus a price of ¥1.53, about +80% upside (undervalued).
What is the fair value of 000078?
Our model-based fair value for Shenzhen Neptunus Bioengineering Co Ltd is ¥2.76 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥1.53.
What is the quality score of 000078?
Shenzhen Neptunus Bioengineering Co Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shenzhen Neptunus Bioengineering Co Ltd (000078)?
Our model-based price target is the fair value of ¥2.76 (as of Sep 24, 2026) from 6 valuation models. Cautious scenario ¥2.54, optimistic scenario ¥2.95. It is a calculation from audited fundamentals, not an analyst target.
What is the Shenzhen Neptunus Bioengineering Co Ltd stock forecast for 2026?
Our models put fair value at ¥2.76, about +80% upside versus a price of ¥1.53 (undervalued). Cautious scenario ¥2.54, optimistic scenario ¥2.95. The calculation is refreshed regularly with new filings.
What is the revenue of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
Shenzhen Neptunus Bioengineering Co Ltd reported trailing-twelve-month revenue of about 25.2B CNY (latest available figure, as of Sep 24, 2026).
Does Shenzhen Neptunus Bioengineering Co Ltd pay a dividend?
Shenzhen Neptunus Bioengineering Co Ltd currently shows a dividend yield of about 11.02% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shenzhen Neptunus Bioengineering Co Ltd it is ¥2.76 per share (as of Sep 24, 2026), against a price of ¥1.53. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Shenzhen Neptunus Bioengineering Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 000078 trades below its calculated fair value: price ¥1.53, fair value ¥2.76, a gap of about +80% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000078?
No. The price is what the market pays today (¥1.53); the fair value is what the company's own numbers justify (¥2.76). For Shenzhen Neptunus Bioengineering Co Ltd the two are ¥1.23 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shenzhen Neptunus Bioengineering Co Ltd worth?
The market values Shenzhen Neptunus Bioengineering Co Ltd at about 4.7B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥1.53; our models calculate a fair value of ¥2.76 per share.
What do the bullish and bearish scenarios say about 000078?
Our models span a range for Shenzhen Neptunus Bioengineering Co Ltd: cautious scenario ¥2.54, base ¥2.76, optimistic ¥2.95 per share (as of Sep 24, 2026, price ¥1.53). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
Balance-sheet figures for Shenzhen Neptunus Bioengineering Co Ltd (as of Sep 24, 2026): return on equity −22.8%, debt of 0.30 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 000078 from its 52-week high?
Shenzhen Neptunus Bioengineering Co Ltd trades at ¥1.53, about 71% below its 52-week high of ¥5.29 and 19% above the low of ¥1.29 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.76 is for.
Which stocks are comparable to Shenzhen Neptunus Bioengineering Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shenzhen Neptunus Bioengineering Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥1.53, calculated fair value ¥2.76 (+80%), Quality Score 40/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000078 calculated?
We run Shenzhen Neptunus Bioengineering Co Ltd through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥2.76, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Shenzhen Neptunus Bioengineering Co Ltd currently trades 80 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
The closing price on Sep 22, 2026 was ¥1.53. Our model-based fair value is ¥2.76, about +80% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shenzhen Neptunus Bioengineering Co Ltd right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (¥2.54). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Shenzhen Neptunus Bioengineering Co Ltd
How large is the market capitalisation of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
The market capitalisation of Shenzhen Neptunus Bioengineering Co Ltd is 4.7B CNY (≈ $695M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
The price-to-sales ratio of Shenzhen Neptunus Bioengineering Co Ltd is 0.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
Earnings per share at Shenzhen Neptunus Bioengineering Co Ltd are ¥−0.2200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
The dividend yield of Shenzhen Neptunus Bioengineering Co Ltd is 11.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
The net margin of Shenzhen Neptunus Bioengineering Co Ltd is −2.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
The return on equity (ROE) of Shenzhen Neptunus Bioengineering Co Ltd is −22.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
On an EBIT basis the return on assets of Shenzhen Neptunus Bioengineering Co Ltd is −1.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shenzhen Neptunus Bioengineering Co Ltd (000078)?
The operating margin of Shenzhen Neptunus Bioengineering Co Ltd is 3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shenzhen Neptunus Bioengineering Co Ltd (000078)?
Revenue at Shenzhen Neptunus Bioengineering Co Ltd is growing −19.4% versus a year earlier (3y avg −11.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shenzhen Neptunus Bioengineering Co Ltd (000078)?
Earnings per share at Shenzhen Neptunus Bioengineering Co Ltd are growing −38.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shenzhen Neptunus Bioengineering Co Ltd (000078) generate?
The free cash flow of Shenzhen Neptunus Bioengineering Co Ltd is −22.7M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shenzhen Neptunus Bioengineering Co Ltd (000078) carry?
The net debt of Shenzhen Neptunus Bioengineering Co Ltd is 8.5B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shenzhen Neptunus Bioengineering Co Ltd in the live analysis
One click puts Shenzhen Neptunus Bioengineering Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
